Therapeutic Vaccination in Chronic Hepatitis B: A Systematic Assessment by the HeberNasvac Therapeutic Vaccine Team
Authors:
- Julio Cesar AguilarJulio Cesar Aguilar
- Sheikh Mohammad Fazle AkbarSheikh Mohammad Fazle Akbar
- Mamun Al-MahtabMamun Al-Mahtab
- Carlos Alberto GuzmanCarlos Alberto Guzman
- Guillermo FernandezGuillermo Fernandez
- Jorge AguiarJorge Aguiar
- Marie-Louise MichelMarie-Louise Michel
- Maryline BourgineMaryline Bourgine
- Maria Acelia MarreroMaria Acelia Marrero
- Stephanie TrittelStephanie Trittel
- Thomas EbensenThomas Ebensen
- Peggy RiesePeggy Riese
Preprint
- 19 August 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
The immune system is central in controlling acute hepatitis B infection and in patients resolving chronic hepatitis B (CHB). Given that 221 million (75%) of CHB patients reside in low- and middle-income countries, developing a vaccine with therapeutic properties represents a rational and cost-effective approach more than a romantic endeavor. This review systematically analyses the critical variables related to the safety, efficacy, and effectiveness of CHB treatments. HeberNasvac's experience is revisited to address the challenges and potentialities of therapeutic vaccines, as well as the current roadblocks in research and development, registration, and large-scale implementation.Keywords
All Related Versions
This publication has 87 references indexed in Scilit:
- Should Indications for Antiviral Therapy for Hepatitis B Be Broadened to Include Immune-Tolerant Patients, Inactive Carriers, or Patients in the “Gray Zone”?Current Hepatology Reports, 2024
- Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patientsHepatology International, 2020
- Low‐level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatmentHepatology, 2016
- Discontinuation of oral antivirals in chronic hepatitis B: A systematic reviewHepatology, 2016
- Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus InfectionDigestive Diseases and Sciences, 2014
- Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis BHepatology International, 2013
- Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patientsHepatology International, 2012
- Correlation between serum hepatitis B virus core‐related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patientsJournal of Medical Virology, 2008
- Spontaneous relapse of hepatitis in inactive HBsAg carriersHepatology International, 2007
- In situ distribution of major histocompatibility complex products and viral antigens in chronic hepatitis B virus infection: Evidence that HBc-containing hepatocytes may express HLA-DR antigensHepatology, 1986